EMERYVILLE, California, February 11, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong
EMERYVILLE, California, January 30, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced that the U.S. Food
–NEW DATA FROM MULTIPLE CAR-T PROGRAMS IN MULTIPLE MYELOMA UTILIZING EUREKA’S BINDING DOMAINS –BCMA/MULTIPLE MYELOMA CAR-T PROGRAM LICENSED TO JUNO THERAPEUTICS (NOW CELGENE) –UPDATED DATA
EMERYVILLE, California, November 21, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
–ONE COMPLETE RESPONSE (CR) OBSERVED IN PATIENT WITH METASTATIC LIVER CANCER –COMPANY EXPECTS TO INITIATE MULTICENTER PHASE 1 U.S. CLINICAL TRIALS IN 2019 EMERYVILLE, California,
EMERYVILLE, CA, USA, August 30, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
EMERYVILLE, CA, USA, August 16, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
EMERYVILLE, CA, USA , July 17, 2018 – Eureka Therapeutics Inc. announced today that Boehringer Ingelheim has elected to exercise an option for the exclusive
Emeryville, California, July 16, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
NO CYTOKINE RELEASE SYNDROME OBSERVED TO DATE EMERYVILLE, Calif., June 4, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of